Shanghai Henlius Biotech
Clinical trials sponsored by Shanghai Henlius Biotech, explained in plain language.
Shanghai Henlius Biotech is a biopharmaceutical company developing biosimilars and innovative drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug HLX42 enters first human trial Results expected Sep 2026 (estimated)
- New combo therapy shows promise for aggressive lung cancer in japanese patients Results expected Oct 2026 (estimated)
- New drug combo aims to shrink Hard-to-Treat tumors Results expected Oct 2026 (estimated)
- New drug HLX43 targets tough esophageal cancers Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat nasopharyngeal cancer: targeted drug HLX43 enters phase 2 trial Results expected Nov 2026 (estimated)
-
New Keytruda-Like drug tested in cancer patients after surgery
Disease control OngoingThis study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people who have had surgery for non-small cell lung cancer, melanoma, or kidney cancer. The goal is to see how the drug moves through the body, how safe it is, and how well it works …
Phase 1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The m…
Phase 1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy shows promise for aggressive lung cancer in japanese patients
Disease control OngoingThis study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that has not been treated before. The goal is to see if the combination shrinks tumors and impro…
Phase 2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New immunotherapy combo shows promise for tough lung cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug serplulimab to standard chemoradiotherapy helps people with limited-stage small cell lung cancer live longer and keep the cancer from growing. About 511 participants will receive either serplulimab or a placebo a…
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New lung cancer combo shows promise in Head-to-Head trial
Disease control OngoingThis study compares a new drug, serplulimab, combined with chemotherapy, against an existing drug, atezolizumab, also with chemotherapy, for people with extensive-stage small cell lung cancer who haven't had treatment before. The goal is to see which combination works better at c…
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC